NCT07631338 Low-grade Gliomas in Argentina: Incidence, Survival, and Therapeutic Strategies
| NCT ID | NCT07631338 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospital Italiano de Buenos Aires |
| Condition | Low-grade Glioma |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-04-01 |
| Primary Completion | 2027-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2026-04-01 with a primary completion date of 2027-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Low-grade gliomas (LGG) are slow-growing primary brain tumors (WHO grades I-II), and their incidence, survival, and treatment patterns in middle-income settings such as Argentina remain poorly characterized. This retrospective, multicenter study comprises two complementary cohorts: 1. Cohort 1: The "captive" population covered under the Hospital Italiano de Buenos Aires Health Plan (January 2011-December 2023) to estimate LGG incidence density. 2. Cohort 2: Histologically confirmed LGG patients treated at the major referral centers to describe overall survival (OS) and disease-free survival (DFS) at 1 and 5 years. Demographic, clinical, pathological, and treatment data will be collected in a centralized REDCap database. The primary objective is to describe LGG incidence in Argentina and estimate survival using Kaplan-Meier curves. The secondary objectives include characterizing therapeutic strategies, molecular mutations, and prognostic factors through Cox regression analysis. This registry will fill a critical gap in LGG epidemiology in middle-income countries and generate hypotheses for future research.
Eligibility Criteria
Study population cohort 1 * Inclusion Criteria * Adult patients (≥18 years old) affiliated to the health plan of Hospital Italiano de Buenos Aires. * Documented clinical follow-up of at least 1 year during the study period. * Exclusion Criteria * Patients not affiliated to the health plan of the Hospital Italiano de Buenos Aires. Study population cohort 2 * Inclusion Criteria * Adult patients (≥18 years) with histopathologically confirmed diagnosis of low-grade glioma (WHO grades I and II). * Exclusion Criteria * Incomplete or doubtful diagnosis based on histopathologic and molecular criteria.
Contact & Investigator
Ivan Alfredo Huespe, MD, MPh
STUDY DIRECTOR
Hospital Italiano de Buenos Aires
Frequently Asked Questions
Who can join the NCT07631338 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Low-grade Glioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07631338 currently recruiting?
Yes, NCT07631338 is actively recruiting participants. Contact the research team at ivan.huespe@hospitalitaliano.org.ar for enrollment information.
Where is the NCT07631338 trial being conducted?
This trial is being conducted at Buenos Aires, Argentina, Buenos Aires, Argentina, Córdoba, Argentina, Buenos Aires, Argentina and 2 additional locations.
Who is sponsoring the NCT07631338 clinical trial?
NCT07631338 is sponsored by Hospital Italiano de Buenos Aires. The principal investigator is Ivan Alfredo Huespe, MD, MPh at Hospital Italiano de Buenos Aires. The trial plans to enroll 40 participants.